100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44DK109779
Award Date
5/1/16
Completion Date
3/31/22
Dollars Obligated
$6.6M
Overview
Activity
20
Transactions
20
Subawards
Similar Awards
Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Awardee
Sonomotion Inc. (LLPBLQA2CBU5)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
California, USA
Update #1
Update #2
BURST WAVE LITHOTRIPSY FOR THE TREATMENT OF URETERAL CALCULI
Posted 4/18/16
5
1
2
3
4
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
FIRST-IN-HUMAN FEASIBILITY TRIAL OF BREAK WAVE - THE OFFICE-BASED LITHOTRIPSY SOLUTION - SIGNIFICANCE: THERE IS A NEED FOR A SAFE AND EFFECTIVE OFFICE-BASED LITHOTRIPSY TREATMENT FOR KIDNEY STONES. KIDNEY STONES ARE COMMON; THEY AFFECT NEARLY 10% OF THE US POPULATION AND THE PREVALENCE CONTINUES TO GROW IN PARALLEL WITH DISEASES SUCH AS HIGH BLOOD PRESSURE, DIABETES, AND OBESITY. KIDNEY STONES ARE ALSO ONE OF THE MOST COSTLY UROLOGIC DISEASES IN AMERICA; THE HEALTH CARE BURDEN IN THE US EXCEEDS $10 BILLION ANNUALLY. A SUBSTANTIAL PORTION OF THIS COST IS DUE TO THE APPROXIMATELY ONE MILLION SURGICAL INTERVENTIONS AND 20-40% RATE OF UNPLANNED POST-SURGICAL EVENTS. THIS INCLUDES EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (SWL), A COMMON NONINVASIVE SURGICAL INTERVENTION, AND URETEROSCOPY LASER LITHOTRIPSY (URS), A COMMON ENDOSCOPIC PROCEDURE. BOTH HAVE A 5% OR GREATER RISK OF SIGNIFICANT ADVERSE EVENTS AND, IN THE US, BOTH PROCEDURES ARE CONDUCTED WITHIN A SURGICAL SUITE WITH THE PATIENT ANESTHETIZED. TECHNOLOGY: SONOMOTION IS DEVELOPING AN OFFICE-BASED, NON-INVASIVE, AND ANESTHESIA FREE STONE LITHOTRIPSY SOLUTION FOR KIDNEY AND URETERAL STONES TO REDEFINE THE STANDARD OF CARE FOR MILLIONS OF PEOPLE. BREAK WAVETM (I.E. BWL) IS A NOVEL METHOD OF STONE FRAGMENTATION THAT USES MULTI-CYCLE, LOW-AMPLITUDE PULSES OF ULTRASOUND RATHER THAN SHOCK WAVES TO INDUCE STONE FRACTURE. THIS APPROACH HAS THE POTENTIAL TO REDUCE THE RISK OF INJURY AND THE RATE OF PROCEDURAL COMPLICATIONS, AS WELL AS SIGNIFICANTLY LOWER PROCEDURAL TIME AND COST. FURTHERMORE, THE LOW AMPLITUDE PULSES WILL PRECLUDE THE NEED FOR ANESTHESIA, PROVIDING AN OFFICE-BASED TREATMENT METHOD. THIS COULD ALSO POTENTIALLY PROVIDE AN ATTRACTIVE ALTERNATIVE TO ACTIVE SURVEILLANCE OF AN OBSTRUCTING STONE. PRELIMINARY DATA: IN VITRO STUDIES HAVE SHOWN THE BREAK WAVE TECHNOLOGY IS CAPABLE OF FRAGMENTING MOST COMMON HUMAN STONES INTO FRAGMENT SIZES THAT ARE CONSISTENTLY LESS THAN 1 MM. CLINICAL SIMULATION CONDUCTED IN A PORCINE MODEL INDICATES THE PRESSURE LEVELS REQUIRED TO BREAK STONES ARE BELOW THE PRESSURE LEVELS REQUIRED TO INDUCE RENAL INJURY. SPECIFIC AIMS: AIM 1 IS A 30-PATIENT, PROSPECTIVE, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM FIRST-IN-HUMAN FEASIBILITY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF BREAK WAVE. SUBJECTS PRESENTING WITH UPPER URINARY TRACT STONES WILL BE RECRUITED AS AN ALTERNATIVE TO SWL. EFFECTIVENESS IS TO BE DETERMINED BY STONE PASSAGE, POST-TREATMENT LOW DOSE CT IMAGING, AND THE NEED FOR SECONDARY PROCEDURES; SAFETY IS TO BE EVALUATED THROUGH THE DOCUMENTED OCCURRENCES OF ADVERSE EVENTS, POST-PROCEDURAL IMAGING, UNPLANNED PHYSICIAN/ED VISITS. PROCEDURAL TOLERANCE AND EFFECTIVENESS WILL ALSO BE EVALUATED AT MULTIPLE PRESSURE LEVELS AND AT REDUCED TO NO ANESTHESIA. THE TRIAL WILL BE CONDUCTED ACROSS 4 CENTERS TO DERIVE A BROAD RANGE OF FEEDBACK ACROSS MULTIPLE WELL-ESTABLISHED UROLOGISTS. THROUGHOUT THE TRIAL, SONOMOTION WILL IDENTIFY DEVICE DESIGN AND PROCEDURAL ADJUSTMENTS TO IMPROVE SAFETY AND EFFECTIVENESS, AND IMPLEMENT THOSE CHANGES IN AIM 2. AIM 2 WILL ALSO IMPLEMENT AND TEST EXPANDING THE BEAM WIDTH TO BREAK LARGER STONES AND ACCOMMODATE GREATER PATIENT MOVEMENT. THE OUTCOME OF THIS GRANT WILL BE A CLINICAL-READY SYSTEM TO INITIATE A PIVOTAL CLINICAL TRIAL FOR FDA REGULATORY APPROVAL.
($101)
3/9/23
Not listed
FIRST-IN-HUMAN FEASIBILITY TRIAL OF BREAK WAVE - THE OFFICE-BASED LITHOTRIPSY SOLUTION - SIGNIFICANCE: THERE IS A NEED FOR A SAFE AND EFFECTIVE OFFICE-BASED LITHOTRIPSY TREATMENT FOR KIDNEY STONES. KIDNEY STONES ARE COMMON; THEY AFFECT NEARLY 10% OF THE US POPULATION AND THE PREVALENCE CONTINUES TO GROW IN PARALLEL WITH DISEASES SUCH AS HIGH BLOOD PRESSURE, DIABETES, AND OBESITY. KIDNEY STONES ARE ALSO ONE OF THE MOST COSTLY UROLOGIC DISEASES IN AMERICA; THE HEALTH CARE BURDEN IN THE US EXCEEDS $10 BILLION ANNUALLY. A SUBSTANTIAL PORTION OF THIS COST IS DUE TO THE APPROXIMATELY ONE MILLION SURGICAL INTERVENTIONS AND 20-40% RATE OF UNPLANNED POST-SURGICAL EVENTS. THIS INCLUDES EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (SWL), A COMMON NONINVASIVE SURGICAL INTERVENTION, AND URETEROSCOPY LASER LITHOTRIPSY (URS), A COMMON ENDOSCOPIC PROCEDURE. BOTH HAVE A 5% OR GREATER RISK OF SIGNIFICANT ADVERSE EVENTS AND, IN THE US, BOTH PROCEDURES ARE CONDUCTED WITHIN A SURGICAL SUITE WITH THE PATIENT ANESTHETIZED. TECHNOLOGY: SONOMOTION IS DEVELOPING AN OFFICE-BASED, NON-INVASIVE, AND ANESTHESIA FREE STONE LITHOTRIPSY SOLUTION FOR KIDNEY AND URETERAL STONES TO REDEFINE THE STANDARD OF CARE FOR MILLIONS OF PEOPLE. BREAK WAVETM (I.E. BWL) IS A NOVEL METHOD OF STONE FRAGMENTATION THAT USES MULTI-CYCLE, LOW-AMPLITUDE PULSES OF ULTRASOUND RATHER THAN SHOCK WAVES TO INDUCE STONE FRACTURE. THIS APPROACH HAS THE POTENTIAL TO REDUCE THE RISK OF INJURY AND THE RATE OF PROCEDURAL COMPLICATIONS, AS WELL AS SIGNIFICANTLY LOWER PROCEDURAL TIME AND COST. FURTHERMORE, THE LOW AMPLITUDE PULSES WILL PRECLUDE THE NEED FOR ANESTHESIA, PROVIDING AN OFFICE-BASED TREATMENT METHOD. THIS COULD ALSO POTENTIALLY PROVIDE AN ATTRACTIVE ALTERNATIVE TO ACTIVE SURVEILLANCE OF AN OBSTRUCTING STONE. PRELIMINARY DATA: IN VITRO STUDIES HAVE SHOWN THE BREAK WAVE TECHNOLOGY IS CAPABLE OF FRAGMENTING MOST COMMON HUMAN STONES INTO FRAGMENT SIZES THAT ARE CONSISTENTLY LESS THAN 1 MM. CLINICAL SIMULATION CONDUCTED IN A PORCINE MODEL INDICATES THE PRESSURE LEVELS REQUIRED TO BREAK STONES ARE BELOW THE PRESSURE LEVELS REQUIRED TO INDUCE RENAL INJURY. SPECIFIC AIMS: AIM 1 IS A 30-PATIENT, PROSPECTIVE, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM FIRST-IN-HUMAN FEASIBILITY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF BREAK WAVE. SUBJECTS PRESENTING WITH UPPER URINARY TRACT STONES WILL BE RECRUITED AS AN ALTERNATIVE TO SWL. EFFECTIVENESS IS TO BE DETERMINED BY STONE PASSAGE, POST-TREATMENT LOW DOSE CT IMAGING, AND THE NEED FOR SECONDARY PROCEDURES; SAFETY IS TO BE EVALUATED THROUGH THE DOCUMENTED OCCURRENCES OF ADVERSE EVENTS, POST-PROCEDURAL IMAGING, UNPLANNED PHYSICIAN/ED VISITS. PROCEDURAL TOLERANCE AND EFFECTIVENESS WILL ALSO BE EVALUATED AT MULTIPLE PRESSURE LEVELS AND AT REDUCED TO NO ANESTHESIA. THE TRIAL WILL BE CONDUCTED ACROSS 4 CENTERS TO DERIVE A BROAD RANGE OF FEEDBACK ACROSS MULTIPLE WELL-ESTABLISHED UROLOGISTS. THROUGHOUT THE TRIAL, SONOMOTION WILL IDENTIFY DEVICE DESIGN AND PROCEDURAL ADJUSTMENTS TO IMPROVE SAFETY AND EFFECTIVENESS, AND IMPLEMENT THOSE CHANGES IN AIM 2. AIM 2 WILL ALSO IMPLEMENT AND TEST EXPANDING THE BEAM WIDTH TO BREAK LARGER STONES AND ACCOMMODATE GREATER PATIENT MOVEMENT. THE OUTCOME OF THIS GRANT WILL BE A CLINICAL-READY SYSTEM TO INITIATE A PIVOTAL CLINICAL TRIAL FOR FDA REGULATORY APPROVAL.
$0
12/8/21
Not listed
FIRST-IN-HUMAN FEASIBILITY TRIAL OF BREAK WAVE - THE OFFICE-BASED LITHOTRIPSY SOLUTION - SIGNIFICANCE: THERE IS A NEED FOR A SAFE AND EFFECTIVE OFFICE-BASED LITHOTRIPSY TREATMENT FOR KIDNEY STONES. KIDNEY STONES ARE COMMON; THEY AFFECT NEARLY 10% OF THE US POPULATION AND THE PREVALENCE CONTINUES TO GROW IN PARALLEL WITH DISEASES SUCH AS HIGH BLOOD PRESSURE, DIABETES, AND OBESITY. KIDNEY STONES ARE ALSO ONE OF THE MOST COSTLY UROLOGIC DISEASES IN AMERICA; THE HEALTH CARE BURDEN IN THE US EXCEEDS $10 BILLION ANNUALLY. A SUBSTANTIAL PORTION OF THIS COST IS DUE TO THE APPROXIMATELY ONE MILLION SURGICAL INTERVENTIONS AND 20-40% RATE OF UNPLANNED POST-SURGICAL EVENTS. THIS INCLUDES EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (SWL), A COMMON NONINVASIVE SURGICAL INTERVENTION, AND URETEROSCOPY LASER LITHOTRIPSY (URS), A COMMON ENDOSCOPIC PROCEDURE. BOTH HAVE A 5% OR GREATER RISK OF SIGNIFICANT ADVERSE EVENTS AND, IN THE US, BOTH PROCEDURES ARE CONDUCTED WITHIN A SURGICAL SUITE WITH THE PATIENT ANESTHETIZED. TECHNOLOGY: SONOMOTION IS DEVELOPING AN OFFICE-BASED, NON-INVASIVE, AND ANESTHESIA FREE STONE LITHOTRIPSY SOLUTION FOR KIDNEY AND URETERAL STONES TO REDEFINE THE STANDARD OF CARE FOR MILLIONS OF PEOPLE. BREAK WAVETM (I.E. BWL) IS A NOVEL METHOD OF STONE FRAGMENTATION THAT USES MULTI-CYCLE, LOW-AMPLITUDE PULSES OF ULTRASOUND RATHER THAN SHOCK WAVES TO INDUCE STONE FRACTURE. THIS APPROACH HAS THE POTENTIAL TO REDUCE THE RISK OF INJURY AND THE RATE OF PROCEDURAL COMPLICATIONS, AS WELL AS SIGNIFICANTLY LOWER PROCEDURAL TIME AND COST. FURTHERMORE, THE LOW AMPLITUDE PULSES WILL PRECLUDE THE NEED FOR ANESTHESIA, PROVIDING AN OFFICE-BASED TREATMENT METHOD. THIS COULD ALSO POTENTIALLY PROVIDE AN ATTRACTIVE ALTERNATIVE TO ACTIVE SURVEILLANCE OF AN OBSTRUCTING STONE. PRELIMINARY DATA: IN VITRO STUDIES HAVE SHOWN THE BREAK WAVE TECHNOLOGY IS CAPABLE OF FRAGMENTING MOST COMMON HUMAN STONES INTO FRAGMENT SIZES THAT ARE CONSISTENTLY LESS THAN 1 MM. CLINICAL SIMULATION CONDUCTED IN A PORCINE MODEL INDICATES THE PRESSURE LEVELS REQUIRED TO BREAK STONES ARE BELOW THE PRESSURE LEVELS REQUIRED TO INDUCE RENAL INJURY. SPECIFIC AIMS: AIM 1 IS A 30-PATIENT, PROSPECTIVE, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM FIRST-IN-HUMAN FEASIBILITY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF BREAK WAVE. SUBJECTS PRESENTING WITH UPPER URINARY TRACT STONES WILL BE RECRUITED AS AN ALTERNATIVE TO SWL. EFFECTIVENESS IS TO BE DETERMINED BY STONE PASSAGE, POST-TREATMENT LOW DOSE CT IMAGING, AND THE NEED FOR SECONDARY PROCEDURES; SAFETY IS TO BE EVALUATED THROUGH THE DOCUMENTED OCCURRENCES OF ADVERSE EVENTS, POST-PROCEDURAL IMAGING, UNPLANNED PHYSICIAN/ED VISITS. PROCEDURAL TOLERANCE AND EFFECTIVENESS WILL ALSO BE EVALUATED AT MULTIPLE PRESSURE LEVELS AND AT REDUCED TO NO ANESTHESIA. THE TRIAL WILL BE CONDUCTED ACROSS 4 CENTERS TO DERIVE A BROAD RANGE OF FEEDBACK ACROSS MULTIPLE WELL-ESTABLISHED UROLOGISTS. THROUGHOUT THE TRIAL, SONOMOTION WILL IDENTIFY DEVICE DESIGN AND PROCEDURAL ADJUSTMENTS TO IMPROVE SAFETY AND EFFECTIVENESS, AND IMPLEMENT THOSE CHANGES IN AIM 2. AIM 2 WILL ALSO IMPLEMENT AND TEST EXPANDING THE BEAM WIDTH TO BREAK LARGER STONES AND ACCOMMODATE GREATER PATIENT MOVEMENT. THE OUTCOME OF THIS GRANT WILL BE A CLINICAL-READY SYSTEM TO INITIATE A PIVOTAL CLINICAL TRIAL FOR FDA REGULATORY APPROVAL.
$0
12/8/21
Not listed
FIRST-IN-HUMAN FEASIBILITY TRIAL OF BREAK WAVE - THE OFFICE-BASED LITHOTRIPSY SOLUTION - SIGNIFICANCE: THERE IS A NEED FOR A SAFE AND EFFECTIVE OFFICE-BASED LITHOTRIPSY TREATMENT FOR KIDNEY STONES. KIDNEY STONES ARE COMMON; THEY AFFECT NEARLY 10% OF THE US POPULATION AND THE PREVALENCE CONTINUES TO GROW IN PARALLEL WITH DISEASES SUCH AS HIGH BLOOD PRESSURE, DIABETES, AND OBESITY. KIDNEY STONES ARE ALSO ONE OF THE MOST COSTLY UROLOGIC DISEASES IN AMERICA; THE HEALTH CARE BURDEN IN THE US EXCEEDS $10 BILLION ANNUALLY. A SUBSTANTIAL PORTION OF THIS COST IS DUE TO THE APPROXIMATELY ONE MILLION SURGICAL INTERVENTIONS AND 20-40% RATE OF UNPLANNED POST-SURGICAL EVENTS. THIS INCLUDES EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (SWL), A COMMON NONINVASIVE SURGICAL INTERVENTION, AND URETEROSCOPY LASER LITHOTRIPSY (URS), A COMMON ENDOSCOPIC PROCEDURE. BOTH HAVE A 5% OR GREATER RISK OF SIGNIFICANT ADVERSE EVENTS AND, IN THE US, BOTH PROCEDURES ARE CONDUCTED WITHIN A SURGICAL SUITE WITH THE PATIENT ANESTHETIZED. TECHNOLOGY: SONOMOTION IS DEVELOPING AN OFFICE-BASED, NON-INVASIVE, AND ANESTHESIA FREE STONE LITHOTRIPSY SOLUTION FOR KIDNEY AND URETERAL STONES TO REDEFINE THE STANDARD OF CARE FOR MILLIONS OF PEOPLE. BREAK WAVETM (I.E. BWL) IS A NOVEL METHOD OF STONE FRAGMENTATION THAT USES MULTI-CYCLE, LOW-AMPLITUDE PULSES OF ULTRASOUND RATHER THAN SHOCK WAVES TO INDUCE STONE FRACTURE. THIS APPROACH HAS THE POTENTIAL TO REDUCE THE RISK OF INJURY AND THE RATE OF PROCEDURAL COMPLICATIONS, AS WELL AS SIGNIFICANTLY LOWER PROCEDURAL TIME AND COST. FURTHERMORE, THE LOW AMPLITUDE PULSES WILL PRECLUDE THE NEED FOR ANESTHESIA, PROVIDING AN OFFICE-BASED TREATMENT METHOD. THIS COULD ALSO POTENTIALLY PROVIDE AN ATTRACTIVE ALTERNATIVE TO ACTIVE SURVEILLANCE OF AN OBSTRUCTING STONE. PRELIMINARY DATA: IN VITRO STUDIES HAVE SHOWN THE BREAK WAVE TECHNOLOGY IS CAPABLE OF FRAGMENTING MOST COMMON HUMAN STONES INTO FRAGMENT SIZES THAT ARE CONSISTENTLY LESS THAN 1 MM. CLINICAL SIMULATION CONDUCTED IN A PORCINE MODEL INDICATES THE PRESSURE LEVELS REQUIRED TO BREAK STONES ARE BELOW THE PRESSURE LEVELS REQUIRED TO INDUCE RENAL INJURY. SPECIFIC AIMS: AIM 1 IS A 30-PATIENT, PROSPECTIVE, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM FIRST-IN-HUMAN FEASIBILITY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF BREAK WAVE. SUBJECTS PRESENTING WITH UPPER URINARY TRACT STONES WILL BE RECRUITED AS AN ALTERNATIVE TO SWL. EFFECTIVENESS IS TO BE DETERMINED BY STONE PASSAGE, POST-TREATMENT LOW DOSE CT IMAGING, AND THE NEED FOR SECONDARY PROCEDURES; SAFETY IS TO BE EVALUATED THROUGH THE DOCUMENTED OCCURRENCES OF ADVERSE EVENTS, POST-PROCEDURAL IMAGING, UNPLANNED PHYSICIAN/ED VISITS. PROCEDURAL TOLERANCE AND EFFECTIVENESS WILL ALSO BE EVALUATED AT MULTIPLE PRESSURE LEVELS AND AT REDUCED TO NO ANESTHESIA. THE TRIAL WILL BE CONDUCTED ACROSS 4 CENTERS TO DERIVE A BROAD RANGE OF FEEDBACK ACROSS MULTIPLE WELL-ESTABLISHED UROLOGISTS. THROUGHOUT THE TRIAL, SONOMOTION WILL IDENTIFY DEVICE DESIGN AND PROCEDURAL ADJUSTMENTS TO IMPROVE SAFETY AND EFFECTIVENESS, AND IMPLEMENT THOSE CHANGES IN AIM 2. AIM 2 WILL ALSO IMPLEMENT AND TEST EXPANDING THE BEAM WIDTH TO BREAK LARGER STONES AND ACCOMMODATE GREATER PATIENT MOVEMENT. THE OUTCOME OF THIS GRANT WILL BE A CLINICAL-READY SYSTEM TO INITIATE A PIVOTAL CLINICAL TRIAL FOR FDA REGULATORY APPROVAL.
$0
12/8/21
Not listed
FIRST-IN-HUMAN FEASIBILITY TRIAL OF BREAK WAVE - THE OFFICE-BASED LITHOTRIPSY SOLUTION - SIGNIFICANCE: THERE IS A NEED FOR A SAFE AND EFFECTIVE OFFICE-BASED LITHOTRIPSY TREATMENT FOR KIDNEY STONES. KIDNEY STONES ARE COMMON; THEY AFFECT NEARLY 10% OF THE US POPULATION AND THE PREVALENCE CONTINUES TO GROW IN PARALLEL WITH DISEASES SUCH AS HIGH BLOOD PRESSURE, DIABETES, AND OBESITY. KIDNEY STONES ARE ALSO ONE OF THE MOST COSTLY UROLOGIC DISEASES IN AMERICA; THE HEALTH CARE BURDEN IN THE US EXCEEDS $10 BILLION ANNUALLY. A SUBSTANTIAL PORTION OF THIS COST IS DUE TO THE APPROXIMATELY ONE MILLION SURGICAL INTERVENTIONS AND 20-40% RATE OF UNPLANNED POST-SURGICAL EVENTS. THIS INCLUDES EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (SWL), A COMMON NONINVASIVE SURGICAL INTERVENTION, AND URETEROSCOPY LASER LITHOTRIPSY (URS), A COMMON ENDOSCOPIC PROCEDURE. BOTH HAVE A 5% OR GREATER RISK OF SIGNIFICANT ADVERSE EVENTS AND, IN THE US, BOTH PROCEDURES ARE CONDUCTED WITHIN A SURGICAL SUITE WITH THE PATIENT ANESTHETIZED. TECHNOLOGY: SONOMOTION IS DEVELOPING AN OFFICE-BASED, NON-INVASIVE, AND ANESTHESIA FREE STONE LITHOTRIPSY SOLUTION FOR KIDNEY AND URETERAL STONES TO REDEFINE THE STANDARD OF CARE FOR MILLIONS OF PEOPLE. BREAK WAVETM (I.E. BWL) IS A NOVEL METHOD OF STONE FRAGMENTATION THAT USES MULTI-CYCLE, LOW-AMPLITUDE PULSES OF ULTRASOUND RATHER THAN SHOCK WAVES TO INDUCE STONE FRACTURE. THIS APPROACH HAS THE POTENTIAL TO REDUCE THE RISK OF INJURY AND THE RATE OF PROCEDURAL COMPLICATIONS, AS WELL AS SIGNIFICANTLY LOWER PROCEDURAL TIME AND COST. FURTHERMORE, THE LOW AMPLITUDE PULSES WILL PRECLUDE THE NEED FOR ANESTHESIA, PROVIDING AN OFFICE-BASED TREATMENT METHOD. THIS COULD ALSO POTENTIALLY PROVIDE AN ATTRACTIVE ALTERNATIVE TO ACTIVE SURVEILLANCE OF AN OBSTRUCTING STONE. PRELIMINARY DATA: IN VITRO STUDIES HAVE SHOWN THE BREAK WAVE TECHNOLOGY IS CAPABLE OF FRAGMENTING MOST COMMON HUMAN STONES INTO FRAGMENT SIZES THAT ARE CONSISTENTLY LESS THAN 1 MM. CLINICAL SIMULATION CONDUCTED IN A PORCINE MODEL INDICATES THE PRESSURE LEVELS REQUIRED TO BREAK STONES ARE BELOW THE PRESSURE LEVELS REQUIRED TO INDUCE RENAL INJURY. SPECIFIC AIMS: AIM 1 IS A 30-PATIENT, PROSPECTIVE, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM FIRST-IN-HUMAN FEASIBILITY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF BREAK WAVE. SUBJECTS PRESENTING WITH UPPER URINARY TRACT STONES WILL BE RECRUITED AS AN ALTERNATIVE TO SWL. EFFECTIVENESS IS TO BE DETERMINED BY STONE PASSAGE, POST-TREATMENT LOW DOSE CT IMAGING, AND THE NEED FOR SECONDARY PROCEDURES; SAFETY IS TO BE EVALUATED THROUGH THE DOCUMENTED OCCURRENCES OF ADVERSE EVENTS, POST-PROCEDURAL IMAGING, UNPLANNED PHYSICIAN/ED VISITS. PROCEDURAL TOLERANCE AND EFFECTIVENESS WILL ALSO BE EVALUATED AT MULTIPLE PRESSURE LEVELS AND AT REDUCED TO NO ANESTHESIA. THE TRIAL WILL BE CONDUCTED ACROSS 4 CENTERS TO DERIVE A BROAD RANGE OF FEEDBACK ACROSS MULTIPLE WELL-ESTABLISHED UROLOGISTS. THROUGHOUT THE TRIAL, SONOMOTION WILL IDENTIFY DEVICE DESIGN AND PROCEDURAL ADJUSTMENTS TO IMPROVE SAFETY AND EFFECTIVENESS, AND IMPLEMENT THOSE CHANGES IN AIM 2. AIM 2 WILL ALSO IMPLEMENT AND TEST EXPANDING THE BEAM WIDTH TO BREAK LARGER STONES AND ACCOMMODATE GREATER PATIENT MOVEMENT. THE OUTCOME OF THIS GRANT WILL BE A CLINICAL-READY SYSTEM TO INITIATE A PIVOTAL CLINICAL TRIAL FOR FDA REGULATORY APPROVAL.
$0
4/5/21